A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00148486
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : October 29, 2013
Information provided by:
Boehringer Ingelheim

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2005
  Study Completion Date : No date given